Swiss Healthtech Stock News

Holcim AG has released its full-year 2025 results, reporting sales of CHF 15,724 million versus CHF 16,201 million in 2024 and net income of CHF 13.18 billion compared with CHF 2.93 billion, alongside sharply higher basic earnings per share of CHF 23.85. The contrast between lower sales and very large growth in net income and earnings per share suggests significant non-operational or one-off effects that investors will want to unpack on the 2025 earnings call held on 27 February 2026. We’ll...

Sandoz Group (SWX:SDZ) just wrapped up FY 2025 with second half revenue of US$5.9b, basic EPS of US$1.25 and net income of US$537m. The company has seen revenue move from US$5.3b and a net loss of US$150m in the second half of 2024 to US$5.3b and net income of US$377m in the first half of 2025, before reaching US$5.9b and EPS of US$1.25 in the latest period. This has set up a full year where trailing 12 month net income stands at US$914m and EPS at US$2.12. With a trailing net profit margin...

Feintool International Holding (SWX:FTON) has kicked off FY 2025 with first half revenue of CHF 334.5 million and a basic EPS loss of CHF 0.34, alongside a net income loss of CHF 5.0 million. The company has seen recent half year revenue move from CHF 390.1 million in the first half of 2024 to CHF 329.5 million in the second half of 2024 and now CHF 334.5 million in the first half of 2025, while EPS shifted from a loss of CHF 0.22 to a loss of CHF 2.78 and now a loss of CHF 0.34. This sets up...

Bystronic (SWX:BYS) has opened FY 2025 with first half revenue of CHF304.6 million and a net income loss of CHF12.9 million, keeping the focus squarely on how quickly the group can turn its earnings profile around. The company has seen revenue move from CHF330.9 million in the first half of 2024 to CHF317.4 million in the second half of 2024 and then to CHF304.6 million in the first half of 2025. Net income losses shifted from CHF20.8 million to CHF46.8 million and then to CHF12.9 million...

Roche Holding (SWX:ROG) received FDA acceptance of its New Drug Application for giredestrant in advanced breast cancer. The filing seeks approval for giredestrant in combination therapy for patients with metastatic breast cancer previously treated with CDK4/6 inhibitors. Roche reported positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, a rare kidney disease. Roche, a global pharmaceuticals and diagnostics group, is closely watched for its late stage pipeline...

UBS Group (SWX:UBSG) has announced a series of leadership changes, with new Board nominees Agustín Carstens and Luca Maestri, several long serving directors stepping down, and Lisa Golia taking charge of US wealth management advisers. See our latest analysis for UBS Group. These boardroom changes come as UBS Group’s share price sits at CHF32.01, with a 1 month share price return of 12.95% decline and a year to date share price return of 16.14% decline, even though the 1 year total shareholder...

If you are wondering whether Julius Bär Gruppe is fairly priced or offering value right now, the key is to look past the share price and focus on what different valuation methods are actually saying. The stock most recently closed at CHF 65.60, with returns of a 0.5% decline over 7 days, 2.1% over 30 days, a 0.3% decline year to date, 14.3% over 1 year, 21.5% over 3 years and 47.2% over 5 years. This gives you a mix of shorter term softness and longer term gains to weigh. Recent coverage of...

Avolta (SWX:AVOL) has secured the duty free concession at Shanghai Pudong Terminal 1, a rare win for an international travel retailer in mainland China that reshapes investor attention on its China exposure. See our latest analysis for Avolta. The Shanghai Pudong win comes at a time when Avolta’s CHF51.95 share price has a 30 day share price return of 10.63% and a 90 day share price return of 17.75%. Its 1 year total shareholder return of 30.73% contrasts with a 5 year total shareholder...

EFG International (SWX:EFGN) has attracted fresh attention after reporting full year 2025 results, with net income and earnings per share broadly steady while net interest income declined over the same period. See our latest analysis for EFG International. The earnings release and upcoming March AGM have come after a softer 30 day share price return of 5.22% and a year to date share price return of a 4.83% decline. This is despite the 1 year total shareholder return of 40.71% and 5 year total...

Logitech International (SWX:LOGN) is back in focus after management highlighted firm demand for premium peripherals and enterprise video collaboration, growing China gaming sales, secured memory supply into fiscal 2027, and continued share repurchases and dividend increases. See our latest analysis for Logitech International. At a share price of CHF71.1, Logitech has seen a 2.3% 1 day and 2.3% 7 day share price gain, set against a 90 day share price decline of 21.3% and a 1 year total...

DKSH Holding (SWX:DKSH) has drawn fresh attention after reporting full year 2025 earnings, which showed slightly lower sales and net income, along with board changes and a confirmed CHF 2.50 per share annual dividend. See our latest analysis for DKSH Holding. Against this backdrop, DKSH Holding’s 30 day share price return of 9.28% and 90 day share price return of 11.23% contrast with a 1 year total shareholder return of 9.53% and 3 year total shareholder return of 12.13%. This suggests recent...

Novartis (SWX:NOVN) plans to build a new radioligand therapy manufacturing facility in Denton, Texas. The plant will expand US production capacity for next generation cancer treatments. The project is expected to create specialized jobs and support a more resilient domestic supply chain. For you as an investor, this move highlights how Novartis is leaning further into radioligand therapies, a targeted cancer treatment area that has drawn growing interest in oncology. The Denton site adds to...

Amrize (SWX:AMRZ) has appointed Ernst & Young LLP (EY US) as its new independent registered public accounting firm, moving from EY Switzerland. The company has reshaped its board structure, including naming a new Chair for the Audit Committee and adding a board member with audit expertise. These governance changes focus on audit oversight, internal controls and financial reporting processes. For investors watching Amrize at a share price of CHF49.27, the shift to EY US and the refreshed...

Schindler Holding AG has reported full-year 2025 results, with sales of CHF 10,947 million and net income of CHF 1,015 million, and has approved an annual dividend of CHF 6.00 per share payable on March 30, 2026. The combination of higher net income and earnings per share, despite slightly lower sales, alongside the confirmed cash return to shareholders, underlines the group’s ability to convert revenue into profit and maintain shareholder distributions. Against this backdrop of higher...

Earnings and dividend move into focus ALSO Holding (SWX:ALSN) reported full year 2025 results with sales of €13,501.23m and net income of €109.33m, alongside a higher annual dividend of CHF 5.30 per share. See our latest analysis for ALSO Holding. The earnings release, dividend increase and earnings call arrived after a tough stretch for shareholders, with the 1 year total shareholder return at a 40.5% loss and the year to date share price return at a 24.7% loss. However, the 7 day share...

Georg Fischer FY 2025 earnings snapshot Georg Fischer (SWX:GF) has opened FY 2025 with first half revenue of CHF2.3b and basic EPS of CHF1.95, alongside net income excluding extra items of CHF160m, setting a clear marker for its latest performance. The company has seen first half revenue shift from CHF1.96b in 2023 to CHF2.41b in 2024 and then to CHF2.26b in 2025, while basic EPS moved from CHF1.50 to CHF1.18 and then to CHF1.95 over the same periods. This gives investors a clearer view of...

Sandoz Group (SWX:SDZ) has drawn fresh attention after reporting full year 2025 earnings, with sales of US$11,086 million and net income of US$914 million, alongside progress in its expanding biosimilars portfolio. See our latest analysis for Sandoz Group. Sandoz Group's 1 day share price return of 2.87% contrasts with a 7 day share price return of 4.64% and a 90 day share price return of 24.01%. The 1 year total shareholder return of 80.41% points to strong momentum around its biosimilars...

Latest earnings snapshot Walliser Kantonalbank (SWX:WKBN) has just posted FY 2025 numbers, with first half revenue of CHF 135.7m and net income (excluding extra items) of CHF 61.0m. This helps indicate how its profitability is holding up. The bank has seen revenue move from CHF 140.7m in 1H 2024 to CHF 154.1m in 2H 2024, and then to CHF 135.7m in 1H 2025. Over the same periods, net income shifted from CHF 66.0m to CHF 69.4m, and then to CHF 61.0m. These figures give investors a clearer view...

Adecco Group (SWX:ADEN) lays out its FY 2025 scorecard Adecco Group (SWX:ADEN) has put its FY 2025 numbers on the table, with fourth quarter revenue of €5.96b, basic EPS of €0.52 and net income of €88m, alongside trailing twelve month revenue of €23.08b and basic EPS of €1.76. Over recent periods the company has seen quarterly revenue move between €5.57b and €5.96b, while basic EPS has ranged from €0.35 to €0.59 and trailing twelve month EPS has sat between €1.67 and €1.81. This gives...

Partners Group Holding (SWX:PGHN) plans to open an office in Kuwait, subject to regulatory approval. The move is intended to expand the firm's presence across the Gulf Cooperation Council region. The new office is expected to support local economic diversification efforts and private markets activity. Partners Group is a global private markets investment firm, and the Kuwait office fits into its broader push to be closer to large institutional and sovereign clients in the Gulf. For...

UBS Group (SWX:UBSG) has promoted Lisa Golia to oversee U.S. financial advisors within its Global Wealth Management division. The bank has also rehired Andrew Bird as head of global wealth management in Australia. UBS Global Research is flagging growing risks in private credit markets linked to AI driven disruption, with expectations for higher default rates and wider credit spreads. For you as an investor, these moves sit at the heart of what UBS does: advising and managing money for...

Temenos (SWX:TEMN) has wrapped up FY 2025 with fourth quarter revenue of US$314.6 million and basic EPS of US$0.63, rounding out a trailing twelve month picture that includes revenue of about US$1.1 billion and EPS of US$4.06. Over the past six quarters, revenue has moved between US$232.2 million and US$318.9 million while quarterly EPS ranged from US$0.41 to US$2.34, giving you a clear view of how top line and per share earnings have tracked together through the latest cycle. With a trailing...

Logitech International highlighted steady demand for high end peripherals and enterprise video collaboration products, even as gaming demand differs by region. Management pointed to stronger gaming activity in China alongside softer trends in North America, underscoring mixed regional consumer patterns. The company outlined supply chain plans and reiterated a focus on capital deployment, including M&A and a sizeable share repurchase program. For investors watching SWX:LOGN, the latest...

Julius Bär Gruppe (SWX:BAER) has appointed Winfried Daun as Global Head of Brand & Marketing in a newly created leadership role. The company has introduced new model portfolios for UK financial advisers as part of an expanded UK wealth management approach. Julius Bär Gruppe, a Swiss private banking group, focuses on wealth management services for high net worth and ultra high net worth clients. The new marketing appointment and the UK model portfolios arrive as many wealth managers look to...